Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brenda Schiesel

Plastic and Reconstructive Surgery Tulsa, OK Doctor of Osteopathy

NPI 1346476579 CMS profile 1377307

10131 S Yale Ave Ste B, Tulsa, OK 74137

Open in the dashboard

General payments

$2,031

46 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brenda Schiesel of Tulsa, OK is reported in the CMS Open Payments database as having received $2,031 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $416 15
2024 General $88 4
2023 General $52 2
2022 General $274 9
2021 General $297 5
2020 General $571 8
2019 General $332 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brenda Schiesel
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Brenda Schiesel were reported at $416. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Brenda Schiesel Plastic and Reconstructive Surgery median Middle half National median
2019 $332 $335 $121–$1,264 $163
2020 $571 $162 $57–$417 $114
2021 $297 $245 $89–$735 $132
2022 $274 $325 $120–$932 $149
2023 $52 $343 $129–$999 $160
2024 $88 $390 $141–$1,085 $164
2025 $416 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sientra, Inc. $1,204 14 payments
  2. AbbVie, Inc. $293 12 payments
  3. Allergan Inc. $189 5 payments
  4. Mentor Worldwide LLC $114 5 payments
  5. Motiva USA, LLC $74 2 payments
  6. Integra LifeSciences Corporation $51 1 payment
  7. Galderma Laboratories, L.P. $35 2 payments
  8. Revance Therapeutics, Inc. $22 1 payment
  9. Heron Therapeutics, Inc. $20 1 payment
  10. Ethicon US, LLC $19 1 payment
  11. Other $10 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,031 46 payments
Products named General payments · program years 2019–2025
  1. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,204 14 payments
  2. BOTOX $276 12 payments
  3. REVOLVE $124 1 payment
  4. MENTOR MemoryGel Resterilizable Gel Sizer $114 5 payments
  5. Motiva Implant Matrix $74 2 payments
  6. Integra Recon-Skin And Wound $51 1 payment
  7. Integra Recon-Skin And Wound $51 1 payment
  8. INTEGRA DERMAL REGENERATION TEMPLATE $51 1 payment
  9. OMNIGRAFT $51 1 payment
  10. SURGIMEND $51 1 payment
  11. Other $103 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record